Weekly Clinical Updates

Real-world Effectiveness of Nirmatrelvir-Ritonavir and Molnupiravir in Non-hospitalised Adults with Covid-19: A Population-based, Retrospective Cohort Study (sic) Cohort Study | Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated with Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial | Post-acute Sequelae of SARS-CoV-2 Cardiovascular Symptoms are Associated with Trace-level Cytokines that Affect Cardiomyocyte Function

Symptoms Six Weeks After COVID-19 are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021–April 2022 | Microbial Dynamics and Pulmonary Immune Responses in COVID-19 Secondary Bacterial Pneumonia | Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Repeated COVID-19 mRNA-based Vaccination Contributes to SARS-CoV-2 Neutralizing Antibody Responses in the Mucosa | SARS-CoV-2 XBB.1.5 mRNA Booster Vaccination Elicits Limited Mucosal Immunity | Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022 | Nirmatrelvir Plus Ritonavir Reduces COVID-19 Hospitalization and Prevents Long COVID in Adult Outpatients | Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo - The ACTIV-6 Randomized Clinical Trial | Clinical and Functional Assessment of SARS-CoV-2 Sequelae among Young Marines – A Panel Study

The Risk of SARS-CoV-2 Transmission in Community Indoor Settings | Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents | Viral and Symptom Rebound Following Anti-SARS-CoV-2 Monoclonal Antibody Therapy in a Randomized Placebo-controlled Trial | The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19 | The Persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 Infection

Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries | Remdesivir-associated Survival Outcomes among Immunocompromised Patients Hospitalized for COVID-19 | Remdesivir Effectiveness in Reducing the Risk of 30-day Readmission in Vulnerable Patients | Measurement of Circulating Viral Antigens Post-SARS-CoV-2 Infection in a Multicohort Study | Driving Under the Cognitive Influence of COVID-19 | Long COVID Facts and Findings

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO) | COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type | Quantitative Susceptibility Mapping at 7 T in COVID-19: Brainstem Effects and Outcome Associations